Drug Trial Radar · NCT05860465
Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: Jan 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
254
Planned (sponsor's estimate)
Start
Sep 8, 2023
Primary completion
Dec 1, 2026
Study completion Dec 30, 2026
Sponsor
- Lead sponsor
- Shanghai Pharmaceuticals Holding Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- May 16, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluated the safety and efficacy of SPH4336 in combination with endocrine therapy in the treatment of locally advanced or metastatic breast cancer that progressed on CDK4/6 inhibitor combined with endocrine therapy.
Conditions
- Locally Advanced or Metastatic Breast Cancer
Interventions
SPH4336 TabletsDrug
SPH4336 Tablets :Administered by oral; Letrozole tablets:Administered by oral; Fulvestrant injection:Administered by intravenous infusion
SPH4336 Tablets PlaceboDrug
SPH4336 Tablets Placebo :Administered by oral; Letrozole tablets:Administered by oral; Fulvestrant injection:Administered by intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rateTime frame: Approximately 3years
- Progression-free survival (PFS)Time frame: Approximately 3years
Locations
22 sites in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, China · Recruiting
The First Affiliated Hospital of Bengbu Medical College
Bengbu, China · Recruiting
Fujian Cancer Hospital
Fuzhou, China · Recruiting
First Affiliated Hospital of Kunming Medical University
Kunming, China · Recruiting
Shenzhen Hospital of University of Hong Kong
Shenzhen, China · Recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China · Recruiting
Affiliated Cancer Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China · Recruiting
Liuzhou people's Hospital
Liuzhou, Guangxi, China · Recruiting
Anyang Cancer Hospital
Anyang, He'nan, China · Recruiting
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, He'nan, China · Recruiting
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China · Recruiting
Harbin Medical University cancer Hospital
Harbin, Heilongjiang, China · Recruiting
Xiangyang Cancer Hospital
Wuhan, Hubei, China · Recruiting
Jiangsu Cancer Hospital
Nanjing, Jiangsu, China · Recruiting
Jiangsu Province Hospital
Nanjing, Jiangsu, China · Recruiting
Jilin Cancer Hospital
Changchun, Jilin, China · Recruiting
The First Hospital of China Medical University
Shenyang, Liaoning, China · Recruiting
General Hospital of Ningxia Medical University
Yinchuan, Ningxia, China · Recruiting
The First Affiliated Hospital of Xi'an Jiao Tong University
Xi’an, Shanxi, China · Recruiting
The second people's hospital of neijiang
Neijiang, Sichuan, China · Recruiting
Yunnan Cancer Hospital
Kunming, Yunnan, China · Recruiting
Zhejiang cancer Hospital
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.